Recombinant Human Interleukin-36 beta, 153a.a.
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. It has two isoforms. IL-36β isoform 2 contains one potential N-linked glycosylation site in its C-terminus, while IL-36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Human IL-36βisoform 2 shares 62 %, 67 %, 63 % and 59 % a.a. identity with the most similar isoform of mouse, canine, bovine and equine IL-36β, respectively.
Reference
1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25
2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973
3. Magne D, Palmer G, Barton JL, et al. 2006. Arthritis Res Ther. 8:R80
4. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2010. Obesity (Silver Spring). 18:2234-6
5. Johnston A, Xing X, Guzman AM, et al. 2011. J Immunol. 186:2613-22.
| Gene ID | 27177 |
| Accession # | Q9NZH7-2 |
| Alternate Names | FIL1 eta, IL-1 eta, IL-1F8, IL-1H2 |
| Source | Escherichia coli. |
| M.Wt | Approximately 17.2 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids. |
| AA Sequence | REAAPKSYAI RDSRQMVWVL SGNSLIAAPL SRSIKPVTLH LIACRDTEFS DKEKGNMVYL GIKGKDLCLF CAEIQGKPTL QLKEKNIMDL YVEKKAQKPF LFFHNKEGST SVFQSVSYPG WFIATSTTSG QPIFLTKERG ITNNTNFYLD SVE |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by inducing IL-8 secretion in human preadipocytes is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105IU/mg. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rHuIL-36β, 153a.a. as determined by LAL method.